Wide variability in addiction medicine training and treatment have prevented far too many Americans from accessing evidence-based care for this chronic, treatable disease

Standardize It: Delivery of Addiction Care

Standardize adm care

ASAM advocates for the use of nationally recognized guidelines and standards for the treatment of addiction and the dissemination of competency-based addiction education for all healthcare professionals.

Advocacy Action

ASAM Weighs in on ONDCP’s 2022 National Drug Control Strategy

July 6, 2021

 

On July 6, ASAM sent a letter to the Office of National Drug Control Policy (ONDCP) responding to a request for input on its 2022 National Drug Control Strategy. ASAM’s comments include recommendations that would strengthen the addiction medicine workforce, standardize the delivery of individualized addiction care, ensure equitable access and coverage for comprehensive, high-quality addiction care, and reduce barriers to accessing evidence-based addiction treatment.

 

Specifically, ASAM’s letter urged ONDCP to advance initiatives in alignment with a plethora of legislation under consideration by Congress. These efforts include legislation to improve access to addiction treatment for individuals who are incarcerated, increase access to care through Medicaid, empower clinicians to treat addiction through telehealth, and improve parity compliance among various insurers. 

 

ASAM also encouraged ONDCP to implement other initiatives to combat the country’s addiction crisis. These initiatives include encouraging state Medicaid programs to adopt two new sets of bundled G codes, approval of a prescription to over the counter (OTC) switch for at least one naloxone product, and regulatory changes that would allow Medicaid reimbursement for the room and board portion of SUD residential levels of care that meet certain standards, among many other efforts. 

 

Read the letter here.

 

 

National Initiatives

Modernizing 42 CFR Part 2

ASAM works to reform 42 CFR Part 2 to ensure that patient privacy is protected and clinicians are not subject onerous administrative burdens that delay or prevent the delivery of care. 

 

MATE Act of 2021

H.R. 2067, the MATE Act of 2021, would require controlled medication prescribers (excluding veterinarians and dentists) to attest – on either one initial or renewal DEA application – that they are an addiction specialist physician or have completed at least 8 hours of qualifying education on treating and managing patients with SUD from one or more accredited organizations or an accredited health professional school or residency program. This will help normalize and mainstream addiction medicine/psychiatry education. In addition, the bill would authorize federal grants to professional associations, universities, and other schools to develop and implement high-quality, comprehensive SUD curriculum for the purpose of integrating SUD education into the standard curriculum of relevant healthcare and health services education programs. Importantly, the legislation would not prevent prescribers from using the same education to satisfy both the one-time DEA registration requirement and for other purposes, such as satisfying state licensing requirements. 

Click here to read a Statement by Leading Stakeholders.

 

H.R. 6 - SUPPORT for Patients and Communities Act

The SUPPORT for Patients and Communities Act was signed into law on October 24, 2018. The bill contains many provisions designed to standardize the delivery of addiction treatment. You can read a section by section summary of the bill here

  • Directs SAMHSA to provide information for entities applying for grants or cooperative agreements from SAMHSA to encourage the implementation & replication of evidence-based practices
  • Authorizes new grant resources ($10M for each of FY 2019 - 2023) for hospitals and other entities to develop protocols on discharging patients who have presented with an opioid overdose. Protocols would address the provision of an overdose reversal medication, such as naloxone, upon discharge, connection with peer-support specialists, and the referral to treatment and other services that best fit the patient’s needs
  • Oct. 1, 2019 - Sept. 30, 2023: State Medicaid plan amendment option to cover inpatient/residential treatment in facilities with more than 16 beds
    • 30 days for 12 month period
    • Must cover certain ASAM Levels of Care
    • Must ensure eligible individuals receive evidence-based assessments
    • Eligible facilities must follow evidence-based practices and offer at least 2 forms of MAT onsite, including in the case of MAT for OUD, at least one antagonist and one partial agonist
    • On November 6, 2019, CMS issued a State Medicaid Director Letter Regarding Implementation of Section 5052 of the SUPPORT for Patients and Communities Act – State Plan Option under Section 1915(l) of the Social Security Act. 

Subscribe to the ASAM Advocate

Your source for timely, useful news briefings of top stories in addiction policy.